The estimated Net Worth of Jessica Oien is at least $100 ezer dollars as of 5 January 2021. Ms. Oien owns over 2,001 units of Cidara Therapeutics Inc stock worth over $90,218 and over the last 6 years she sold CDTX stock worth over $9,904. In addition, she makes $0 as General Counsel és Secretary at Cidara Therapeutics Inc.
Jessica has made over 3 trades of the Cidara Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 2,001 units of CDTX stock worth $4,822 on 5 January 2021.
The largest trade she's ever made was selling 2,001 units of Cidara Therapeutics Inc stock on 5 January 2021 worth over $4,822. On average, Jessica trades about 480 units every 58 days since 2019. As of 5 January 2021 she still owns at least 7,764 units of Cidara Therapeutics Inc stock.
You can see the complete history of Ms. Oien stock trades at the bottom of the page.
Jessica Oien J.D. serves as General Counsel, Secretary of the Company. Prior to joining Cidara, Ms. Oien served as Vice President, Compliance at Otonomy, Inc., where she developed and oversaw the commercial compliance program and was the legal lead for the commercial business. Ms. Oien served in similar roles as Vice President, Compliance for Pernix Therapeutics, Vice President, Legal Affairs & Compliance for Somaxon Pharmaceuticals, Inc., and Senior Director, Legal Affairs for Verus Pharmaceuticals. Ms. Oien provided legal consulting services for a robust clientele of early stage biotech companies providing legal support for numerous collaborations, and other research and development programs. Ms. Oien also served as Senior Director, Legal Affairs at Elan Corporation. Ms. Oien began her legal career as outside corporate counsel at national law firms including tenures at Brobeck, Phleger & Harrison and Milbank, Tweed, Hadley & McCloy. Ms. Oien received her J.D. from Loyola Law School and a B.A. in Economics and Political Science from North Dakota State University.
Jessica Oien is 49, she's been the General Counsel és Secretary of Cidara Therapeutics Inc since 2018. There are 11 older and 5 younger executives at Cidara Therapeutics Inc. The oldest executive at Cidara Therapeutics Inc is Dr. Kenneth F. Bartizal Ph.D., 70, who is the Chief Devel. Officer.
Jessica's mailing address filed with the SEC is 6310 Nancy Ridge Dr #101, San Diego, CA 92121, USA.
Over the last 15 years, insiders at Cidara Therapeutics Inc have traded over $256,071 worth of Cidara Therapeutics Inc stock and bought 1,216,676 units worth $9,796,257 . The most active insiders traders include Capital Management, L.P.Ra ..., Target N Vbb Biotech Ag Bio... és Steve Elms. On average, Cidara Therapeutics Inc executives and independent directors trade stock every 52 days with the average trade being worth of $282,598. The most recent stock trade was executed by Jeffrey Stein on 7 June 2024, trading 8,000 units of CDTX stock currently worth $105,680.
cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.
Cidara Therapeutics Inc executives and other stock owners filed with the SEC include: